New drug combo aims to fight tough cancers

NCT ID NCT07038096

Recruiting now Disease control Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental drugs, ZG006 and ZG005, given together by IV in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial aims to see if the combination is safe and can shrink tumors. About 350 adults aged 18 to 70 are being recruited at multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZG006 and ZG005 (two experimental drugs given by IV infusion)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced small cell lung cancer or neuroendocrine carcinoma, potentially shrinking tumors and extending survival.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drugs may not work as hoped or could cause serious side effects. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE; CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE; CARCINOMA SMALL CELL LUNG CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guanzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.